[go: up one dir, main page]

CA2933480A1 - Inhibiteur de la demethylase-1 specifique de la lysine - Google Patents

Inhibiteur de la demethylase-1 specifique de la lysine Download PDF

Info

Publication number
CA2933480A1
CA2933480A1 CA2933480A CA2933480A CA2933480A1 CA 2933480 A1 CA2933480 A1 CA 2933480A1 CA 2933480 A CA2933480 A CA 2933480A CA 2933480 A CA2933480 A CA 2933480A CA 2933480 A1 CA2933480 A1 CA 2933480A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
heterocyclyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2933480A
Other languages
English (en)
Other versions
CA2933480C (fr
Inventor
Young K. Chen
Toufike Kanouni
Stephen W. Kaldor
Jeffrey Alan Stafford
James Marvin Veal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Priority to CA3161836A priority Critical patent/CA3161836A1/fr
Publication of CA2933480A1 publication Critical patent/CA2933480A1/fr
Application granted granted Critical
Publication of CA2933480C publication Critical patent/CA2933480C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne, d'une manière générale, des compositions et des méthodes de traitement du cancer et de maladies néoplasiques. La présente invention concerne des composés dérivés hétérocycliques substitués et des compositions pharmaceutiques contenant ces composés. Les composés et compositions selon l'invention sont utiles pour l'inhibition de la déméthylase-1 spécifique de la lysine. De plus, les composés et compositions selon l'invention sont utiles pour le traitement du cancer, tel que le cancer de la prostate, le cancer du sein, le cancer de la vessie, le cancer du poumon et/ou le mélanome et analogues.
CA2933480A 2013-12-11 2014-12-10 Inhibiteur de la demethylase-1 specifique de la lysine Active CA2933480C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3161836A CA3161836A1 (fr) 2013-12-11 2014-12-10 Inhibiteur de la demethylase-1 specifique de la lysine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914927P 2013-12-11 2013-12-11
US61/914,927 2013-12-11
PCT/US2014/069562 WO2015089192A1 (fr) 2013-12-11 2014-12-10 Inhibiteur de la déméthylase-1 spécifique de la lysine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3161836A Division CA3161836A1 (fr) 2013-12-11 2014-12-10 Inhibiteur de la demethylase-1 specifique de la lysine

Publications (2)

Publication Number Publication Date
CA2933480A1 true CA2933480A1 (fr) 2015-06-18
CA2933480C CA2933480C (fr) 2022-08-23

Family

ID=53371806

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3161836A Pending CA3161836A1 (fr) 2013-12-11 2014-12-10 Inhibiteur de la demethylase-1 specifique de la lysine
CA2933480A Active CA2933480C (fr) 2013-12-11 2014-12-10 Inhibiteur de la demethylase-1 specifique de la lysine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3161836A Pending CA3161836A1 (fr) 2013-12-11 2014-12-10 Inhibiteur de la demethylase-1 specifique de la lysine

Country Status (17)

Country Link
US (3) US9944636B2 (fr)
EP (2) EP4257591A3 (fr)
JP (1) JP6430512B2 (fr)
CA (2) CA3161836A1 (fr)
DK (1) DK3080100T3 (fr)
ES (1) ES2935746T3 (fr)
FI (1) FI3080100T3 (fr)
HR (1) HRP20230086T1 (fr)
HU (1) HUE061252T2 (fr)
LT (1) LT3080100T (fr)
MX (2) MX376047B (fr)
PL (1) PL3080100T3 (fr)
PT (1) PT3080100T (fr)
RS (1) RS63939B1 (fr)
SI (1) SI3080100T1 (fr)
SM (1) SMT202300014T1 (fr)
WO (1) WO2015089192A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
HRP20220096T1 (hr) * 2014-05-01 2022-04-15 Celgene Quanticel Research, Inc. Inhibitori lizin specifične demetilaze-1
LT3160956T (lt) * 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
EA201891526A3 (ru) * 2014-07-03 2019-05-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы лизин-специфической деметилазы-1
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
MX381597B (es) * 2014-09-05 2025-03-12 Celgene Quanticel Res Inc Inhibidores demetilasa-1 específica de lisina.
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (fr) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci
EA035534B1 (ru) 2015-08-12 2020-06-30 Инсайт Корпорейшн Соли ингибитора lsd1
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
CA3006434C (fr) 2015-11-27 2021-03-16 Taiho Pharmaceutical Co., Ltd. Compose de biphenyle ou un sel de celui-ci
SG11201805645QA (en) 2015-12-29 2018-07-30 Mirati Therapeutics Inc Lsd1 inhibitors
CA3017411C (fr) 2016-03-15 2024-06-25 Oryzon Genomics, S.A. Combinaisons d'inhibiteurs de lsd1 pour leur utilisation dans le traitement des tumeurs solides
EP3430015B9 (fr) 2016-03-16 2025-12-31 Oryzon Genomics, S.A. Procédés de détermination de l'engagement d'une cible kdm1a et chimiosondes utiles correspondantes
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
BR112018071585B1 (pt) 2016-04-22 2024-01-02 Incyte Corporation Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
CN105924397B (zh) * 2016-04-29 2017-11-24 河南省农业科学院植物保护研究所 一种1,5‑二芳基‑3‑甲酸酯吡唑类化合物、制备方法及用途
WO2018083138A1 (fr) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarqueurs pharmacodynamiques pour traitement du cancer personnalisé à l'aide d'agents de modification épigénétique
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
JP7352284B2 (ja) * 2017-05-15 2023-09-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体
RU2765152C2 (ru) 2017-05-26 2022-01-26 Тайхо Фармасьютикал Ко., Лтд. Новое соединение бифенила или его соль
TWI770925B (zh) * 2017-05-26 2022-07-11 日商大鵬藥品工業股份有限公司 使用有新穎聯苯化合物之抗腫瘤效果增強劑
TWI749235B (zh) 2017-05-31 2021-12-11 日商大鵬藥品工業股份有限公司 基於insm1表現之lsd1抑制劑之治療效果的預測方法
AU2018309372B2 (en) 2017-08-03 2024-08-15 Oryzon Genomics, S.A. Methods of treating behavior alterations
TWI794294B (zh) 2017-09-13 2023-03-01 南韓商韓美藥品股份有限公司 吡唑衍生化合物及其用途
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
AU2020242302B2 (en) 2019-03-20 2025-10-30 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
WO2021095835A1 (fr) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. Nouveau sel de composé terphényle
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
AU2022254484A1 (en) 2021-04-08 2023-11-09 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
EP4419504A4 (fr) * 2021-10-18 2025-09-03 Imago Biosciences Inc Inhibiteurs de kdm1a pour le traitement d'une maladie
CN116836167B (zh) * 2022-03-25 2025-09-09 腾讯科技（深圳）有限公司 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途
WO2023217758A1 (fr) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Méthodes de traitement d'une tumeur maligne des gaines des nerfs périphériques (tmgnp) à l'aide d'inhibiteurs de lsd1
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法
KR20250109775A (ko) 2022-11-24 2025-07-17 오리존 지노믹스 에스.에이. 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
JP2005500294A (ja) * 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
JP2005534619A (ja) * 2002-03-28 2005-11-17 エーザイ株式会社 Ｃ−ｊｕｎｎ−末端キナーゼ阻害剤としてのアザインドール
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
WO2007006581A2 (fr) * 2005-07-13 2007-01-18 Universitätsklinikum Freiburg Anticorps destines a etre utilises dans l'identification et/ou l'analyse du cancer de la prostate et regulation de l'expression genique en fonction du recepteur androgene
CA2640398A1 (fr) * 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines ou 4-aryl-2-aminoalkyl-pyrimidines utilisees comme modulateurs de la jak-2 et leurs procedes d'utilisation
PL2152701T3 (pl) * 2007-03-12 2016-10-31 Związki fenyloaminopirymidyny i ich zastosowania
JP5599791B2 (ja) * 2008-07-29 2014-10-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ５−アルキニル−ピリミジン
WO2010046780A2 (fr) * 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
EP2258858A1 (fr) * 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Modèle animal pour le cancer transgénique pour LSD1
EP2258865A1 (fr) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Déméthylase spécifique de la lysine (LSD1) en tant que biomarqueur du cancer du sein
EP2467359A4 (fr) * 2009-08-18 2013-01-09 Univ Johns Hopkins Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles
TW201111378A (en) * 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
WO2011143057A1 (fr) * 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Inhibiteurs inédits de la prolylcarboxypeptidase
WO2012013727A1 (fr) * 2010-07-29 2012-02-02 Oryzon Genomics S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
GB201106829D0 (en) * 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
US9289415B2 (en) 2011-09-01 2016-03-22 The Brigham And Women's Hospital, Inc. Treatment of cancer
AR088351A1 (es) * 2011-10-31 2014-05-28 Lilly Co Eli Analogos de pirazol sustituidos
EP2770994B1 (fr) * 2012-05-04 2019-08-21 Samumed, LLC 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
JP6195828B2 (ja) * 2012-05-24 2017-09-13 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子

Also Published As

Publication number Publication date
LT3080100T (lt) 2023-02-27
HUE061252T2 (hu) 2023-05-28
EP3080100A4 (fr) 2017-09-06
MX2020010496A (es) 2020-10-28
US9944636B2 (en) 2018-04-17
HRP20230086T1 (hr) 2023-03-31
US20160304516A1 (en) 2016-10-20
US10131664B2 (en) 2018-11-20
US20190055242A1 (en) 2019-02-21
FI3080100T3 (fi) 2023-03-15
US20180179204A1 (en) 2018-06-28
EP4257591A2 (fr) 2023-10-11
US10385051B2 (en) 2019-08-20
MX2016007585A (es) 2016-12-16
CA2933480C (fr) 2022-08-23
JP2017502940A (ja) 2017-01-26
JP6430512B2 (ja) 2018-11-28
MX376047B (es) 2025-03-07
EP3080100B1 (fr) 2022-11-30
PL3080100T3 (pl) 2023-03-06
EP3080100A1 (fr) 2016-10-19
EP4257591A3 (fr) 2023-11-22
WO2015089192A1 (fr) 2015-06-18
RS63939B1 (sr) 2023-02-28
SMT202300014T1 (it) 2023-05-12
ES2935746T3 (es) 2023-03-09
CA3161836A1 (fr) 2015-06-18
SI3080100T1 (sl) 2023-04-28
DK3080100T3 (da) 2023-02-06
PT3080100T (pt) 2023-01-19

Similar Documents

Publication Publication Date Title
CA2933480C (fr) Inhibiteur de la demethylase-1 specifique de la lysine
JP6983273B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
US9896449B2 (en) Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
EP2124951B1 (fr) Dérivés de 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine utiles en tant qu'inhibiteurs de la protéine kinase
WO2021011796A1 (fr) Inhibiteurs de kinases dépendantes des cyclines
HK1230202B (en) Inhibitors of lysine specific demethylase-1
HK1230202A1 (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191113

EEER Examination request

Effective date: 20191113